First modification: 28/07/2022 – 17:30Last modification: 28/07/2022 – 17:28
–
New York (AFP) – Sales of the vaccine and the anticovid pill boosted Pfizer’s results in the second quarter, and the group maintains its forecast of sales of these products of 54,000 million dollars by 2022.
Between April and June, the US laboratory’s turnover soared 47% to reach 27.74 billion dollars, a record for the firm.
Meanwhile, net income soared 78% in the period compared to the same quarter last year, to 9.9 billion dollars.
Sales of the Comirnaty coronavirus vaccine, developed in collaboration with the German group BioNTech, reached 8.8 billion dollars (+20% over the same period in 2021), with sales rising in emerging countries and deliveries in some developed countries.
Sales of the anticovid pill Paxlovid, launched in late 2021 and recently used by President Joe Biden, reached $8.1 billion.
The laboratory maintained its forecasts for the full year.
© 2022 AFP
–
